Hadassah and Neurogenesis announce results from Phase 2 MS Study
Posted on
ALS, Bone Marrow, clinical trial, Dimitrios Karussis, Ein Kerem, Hadassah Hospital, Ibrahim Kassis, Israel, MS, Multiple Sclerosis, NeuroGenesis, Petrou Panayiota, Phase 2 Study, Progressive MS, stem cells, Tal Galit, technology, treatment
Donate / Foundation / Future / General / Genetics / Hadassah / Hadassah Heroes / Hospital / News / Nonprofit / Patient Blog / Relief / Research / Uncategorized
A Phase 2 study at Hadassah Hospital Ein Kerem has revealed significant clinical improvements in patients with progressive multiple sclerosis (MS) after being treated with NG-01 stem cells developed by NeuroGenesis, a clinical-stage biopharmaceutical company advancing innovative cell therapies to combat neurodegenerative diseases. The 14-month randomized, double blind, placebo-controlled study, comprised of 48 patients, was led by Prof.…
